The new automated insulin delivery system will be developed to treat type 2 diabetes patients. Credit: Dennis Klicker on Unsplash.

embecta has reached a partnership with Tidepool for the development of an automated insulin delivery (AID) system to treat type 2 diabetes (T2D) patients.

The company will use Tidepool’s diabetes management software expertise to create the AID algorithm for its closed-loop patch pump system.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This system, which received breakthrough device designation from the US Food and Drug Administration (FDA), has been designed to cater to the specific requirements of individuals living with type 2 diabetes.

Tidepool founder and CEO Howard Look said: “Building on the recent FDA clearance for Tidepool Loop, Tidepool is excited to partner with embecta to create tailored solutions for a broader user base including people with type 2 diabetes.”

First established in 2013, Tidepool offers a suite of software tools for individuals with diabetes and healthcare facilities.

These tools include Tidepool Web, Tidepool Mobile, Tidepool Uploader and Tidepool Loop.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

embecta chief medical officer Henry Anhalt said: “The recent 510(k) clearance of Tidepool Loop — a fully interoperable automated insulin dosing app which started as a patient-led initiative — affirms that Tidepool’s approach to AID system development combines patient insights with a robust diabetes management solution.

“We believe that the combination of the embecta and Tidepool teams will lead to the development of a user-centric T2D AID system that fills a need for improved glucose management.”